Literature DB >> 21402995

Rundle and his curve.

George B Bartley1.   

Abstract

Mesh：

Year:  2011        PMID： 21402995     DOI： 10.1001/archophthalmol.2011.29

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  22 in total

1.  Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.

Authors:  Francesca Menconi; Maria Antonietta Profilo; Marenza Leo; Eleonora Sisti; Maria Antonietta Altea; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2013-12-09       Impact factor: 6.568

2.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

3.  Preoperative clinical features of reactivated of Graves' orbitopathy after orbital decompression.

Authors:  Y J Woo; J W Kim; J S Yoon
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

4.  Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients.

Authors:  S Y Jang; S Y Lee; E J Lee; J S Yoon
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

5.  Natural history of graves' orbitopathy after treatment.

Authors:  Francesca Menconi; Marenza Leo; Elena Sabini; Teresa Mautone; Marco Nardi; Aldo Sainato; Stefano Sellari-Franceschini; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Endocrine       Date:  2016-10-05       Impact factor: 3.633

Review 6.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

7.  Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy: A Randomized Clinical Trial.

Authors:  Yuan Pan; Yu-Xi Chen; Jian Zhang; Miao-Li Lin; Guang-Ming Liu; Xue-Liang Xu; Xian-Qun Fan; Yong Zhong; Qing Li; Si-Ming Ai; Wen Xu; Jia Tan; Hui-Fang Zhou; Dong-Dong Xu; Hui-Ying Zhang; Bei Xu; Sha Wang; Jun-Jie Ma; Shuo Zhang; Lin-Yang Gan; Jian-Tao Cui; Li Li; Yan-Yan Xie; Xinxing Guo; Nathan Pan-Doh; Zhuo-Ting Zhu; Yao Lu; Yu-Xun Shi; Yi-Wen Xia; Zuo-Yi Li; Dan Liang
Journal:  JAMA Ophthalmol       Date:  2022-09-29       Impact factor: 8.253

8.  Teprotumumab (Tepezza) for Thyroid Eye Disease.

Authors:  Steven M Couch
Journal:  Mo Med       Date:  2022 Jan-Feb

9.  Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections.

Authors:  Sung Jun Lee; Tyler Hyung Taek Rim; Sun Young Jang; Chan Yun Kim; Dong Yeob Shin; Eun Jig Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-12       Impact factor: 3.117

10.  Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy.

Authors:  Theodora Tsirouki; Alexandra Bargiota; Stelios Tigas; Agathi Vasileiou; Eftichia Kapsalaki; Zoe Giotaki; Ioannis Asproudis; Agathokles Tsatsoulis; Georgios Koukoulis; Evangelia E Tsironi
Journal:  Clin Ophthalmol       Date:  2016-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.